SG11202010423VA - COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER - Google Patents

COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER

Info

Publication number
SG11202010423VA
SG11202010423VA SG11202010423VA SG11202010423VA SG11202010423VA SG 11202010423V A SG11202010423V A SG 11202010423VA SG 11202010423V A SG11202010423V A SG 11202010423VA SG 11202010423V A SG11202010423V A SG 11202010423VA SG 11202010423V A SG11202010423V A SG 11202010423VA
Authority
SG
Singapore
Prior art keywords
tgfß
dna
cancer
treatment
combined inhibition
Prior art date
Application number
SG11202010423VA
Inventor
Yan Lan
Chunxiao Xu
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11202010423VA publication Critical patent/SG11202010423VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202010423VA 2018-05-04 2019-05-06 COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER SG11202010423VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862667263P 2018-05-04 2018-05-04
PCT/EP2019/061558 WO2019211489A1 (en) 2018-05-04 2019-05-06 COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
SG11202010423VA true SG11202010423VA (en) 2020-11-27

Family

ID=66484020

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010423VA SG11202010423VA (en) 2018-05-04 2019-05-06 COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER

Country Status (12)

Country Link
US (1) US20210246208A1 (en)
EP (1) EP3787683A1 (en)
JP (1) JP2021522298A (en)
KR (1) KR20210006405A (en)
CN (1) CN112512576A (en)
AU (1) AU2019264229A1 (en)
BR (1) BR112020022145A2 (en)
CA (1) CA3099079A1 (en)
MX (1) MX2020011684A (en)
SG (1) SG11202010423VA (en)
TW (1) TW202014201A (en)
WO (1) WO2019211489A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118255902A (en) 2017-03-02 2024-06-28 加拿大国家研究委员会 TGF-beta receptor ectodomain fusion molecules and uses thereof
SG11202100208VA (en) * 2018-07-09 2021-02-25 Precigen Inc Fusion constructs and methods of using thereof
MX2022013620A (en) * 2020-04-29 2023-01-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Bifunctional protein against pd-1 and tgf-î².
JP2023553257A (en) * 2020-11-02 2023-12-21 アレス トレーディング ソシエテ アノニム combination therapy for cancer
US20230372319A1 (en) * 2020-11-02 2023-11-23 Ares Trading S.A. Combination Treatment of Cancer
TW202304979A (en) * 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP4358990A1 (en) * 2021-06-24 2024-05-01 Bristol-Myers Squibb Company Transforming growth factor-beta ligand traps for the treatment of disease
WO2023019308A1 (en) * 2021-08-17 2023-02-23 Telix International Pty Ltd Combination radiotherapy
CN116328213A (en) * 2023-05-29 2023-06-27 四川大学华西医院 Use of an LDRT intussusception SBRT system in the manufacture of a device for treating solid tumours

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (en) 1990-01-12 2007-04-15 Amgen Fremont Inc FORMATION OF XENOGENE ANTIBODIES
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK1136556T3 (en) 1991-11-25 2005-10-03 Enzon Inc Process for the preparation of multivalent antigen-binding proteins
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT1500329E (en) 1996-12-03 2012-06-18 Amgen Fremont Inc Human antibodies that specifically bind human tnf alpha
PT1034298E (en) 1997-12-05 2012-02-03 Scripps Research Inst Humanization of murine antibody
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1907424B1 (en) 2005-07-01 2015-07-29 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
KR20100054780A (en) 2007-06-18 2010-05-25 엔.브이.오가논 Antibodies to human programmed death receptor pd-1
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR20200047793A (en) 2008-12-09 2020-05-07 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
JP2013512251A (en) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
PL3279215T3 (en) 2009-11-24 2020-06-29 Medimmune Limited Targeted binding agents against b7-h1
CA2791383C (en) * 2010-03-05 2022-09-20 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
ES2641916T3 (en) 2010-08-31 2017-11-14 Genentech, Inc. Biomarkers and treatment methods
ES2708669T3 (en) 2011-08-01 2019-04-10 Hoffmann La Roche Cancer treatment procedures using PD-1 axis-binding antagonists and MEK inhibitors
RS61033B1 (en) 2011-11-28 2020-12-31 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
AR093984A1 (en) 2012-12-21 2015-07-01 Merck Sharp & Dohme ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
PL3105246T3 (en) 2014-02-10 2021-11-29 Merck Patent Gmbh Targeted tgf beta inhibition
EP3171896A4 (en) * 2014-07-23 2018-03-21 Mayo Foundation for Medical Education and Research Targeting dna-pkcs and b7-h1 to treat cancer
MA40737A (en) * 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO PD-1 BLOCKED IMMUNOTHERAPY
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
AU2016222587B2 (en) * 2015-02-25 2021-01-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating Fanconi Anemia
US10167334B2 (en) * 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
JP7573365B2 (en) * 2016-08-12 2024-10-25 メルク パテント ゲーエムベーハー Combination Cancer Therapy
KR102629503B1 (en) 2017-05-12 2024-01-24 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Fusion protein containing TGF-β receptor and pharmaceutical use thereof

Also Published As

Publication number Publication date
WO2019211489A1 (en) 2019-11-07
CN112512576A (en) 2021-03-16
MX2020011684A (en) 2020-12-10
EP3787683A1 (en) 2021-03-10
JP2021522298A (en) 2021-08-30
TW202014201A (en) 2020-04-16
BR112020022145A2 (en) 2021-01-26
US20210246208A1 (en) 2021-08-12
CA3099079A1 (en) 2019-11-07
KR20210006405A (en) 2021-01-18
AU2019264229A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
SG11202010423VA (en) COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
IL254131A0 (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
IL263178A (en) Pd-1 / pd-l1 inhibitors for cancer treatment
IL272948A (en) Enpp1 inhibitors and their use for the treatment of cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL261015A (en) Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
IL268676A (en) Inhibition of smarca2 for treatment of cancer
EP3606531A4 (en) Methods of treating cancer
EP3615056A4 (en) Methods and agents for the detection and treatment of cancer
EP3589659A4 (en) Compounds and methods for treating cancer
HK1244436A1 (en) Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
IL268163A (en) Methods, compositions, and kits for treatment of cancer
EP3471722A4 (en) Compounds, compositions and methods for prevention and/or treatment of cancer
EP3697767A4 (en) Compounds and methods for treating cancer
EP3630080A4 (en) Use of ezh2 inhibitors for treating cancer
EP3723765A4 (en) Methods of treating cancer
EP3681498A4 (en) Methods and compositions for the treatment of cancer
IL283885A (en) Cxcr7 inhibitors for the treatment of cancer
EP3565530A4 (en) Treatment of pancreatic cancer
IL270948A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3661953A4 (en) Methods and compositions for the treatment of cancer
IL273835A (en) Combination product for the treatment of cancer
EP3538102A4 (en) Inhibition of kmt2d for the treatment of cancer
EP3630754B8 (en) Isoindoline-acetylene compounds for the treatment of cancer
EP3592357A4 (en) Methods of treating cancer